The Multidisciplinary Association for Psychedelic Studies (MAPS) sponsored six Phase 2 studies of MDMA, treating a total of 130 PTSD patients. Phase 3 research will include at least 230 patients, preferentially drawn from a pool of U.S. Armed Forces veterans. Researchers have been so happy with Phase 2 results that they have applied for “breakthrough therapy status” with the FDA, which could fast-track approval of professional MDMA therapy by 2021.
A call for Phase 3 study participants has not yet gone out, but if you are an interested military veteran diagnosed with PTSD and you are in otherwise good health with good blood pressure, you can keep up to date with developments at the MAPS website.
MAPS is also holding the 2017 Psychedelic Science conference in Oakland, California, April 19-24. This is a great opportunity particularly for those in the healthcare field to get more educated about the promise of MDMA and other psychedelic therapies and to meet some of the researchers involved.